Učitavanje...
A Phase II Study of Imatinib Mesylate and Capecitabine in Metastatic Breast Cancer: Southwest Oncology Group Study 0338
PURPOSE: Imatinib mesylate is a potent inhibitor of the Bcr-Abl, c-kit, and platelet-derived growth factor receptor (PDGFR) tyrosine kinases. Based on variable expression of c-kit and PDGFR in breast cancer, and on in vitro data supporting synergy between imatinib and capecitabine, the Southwest Onc...
Spremljeno u:
| Glavni autori: | , , , , , , , , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
2008
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3510680/ https://ncbi.nlm.nih.gov/pubmed/19073506 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3816/CBC.2008.n.062 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|